[QUOTE=Jolande;903339]PPms is mogelijk iets heel anders dan SPms, ik zou ze niet gemakshalve op een hoop gooien Bixi :cool:[/QUOTE]
Goed, je hebt gelijk Jolande misschien, ik heb mij daarin niet verdiept...
Zou het een goed idee zijn om op een lijstje te zetten de middelen waarvoor we uit eigen ervaring weten dat - op bepaalde symptoom verlichting gafen....?
B.v.b. - Mariadistel helpt mij om darmbewegingen in goede orde te houden...
- tuhuo loranthus combination - chineese kruiden helpen mij bij tremor...
Mino hielp bij dubbelzien ne nystagmus (en nog meer..)
Zou dit lijstje wat leveren zonder dat iemand beledigd wordt denk je...?
CCSVI & Minocycline
-
Jolande
Goed idee Bixi
Waarom zou iemand zich beledigd voelen, als maar duidelijk is dat het om persoonlijke ervaringen gaat en er niet weer mensen gaan prediken dat er een alles helend wondermiddel tussen zit, dat blinde fanatisme vind ik altijd erg storend en jammer
Ook liever geen voorbarige conclusies aan koppelen van 'glutenvrij en vitamine d heeft mijn ms gestopt' of iets van gelijke strekking.
Pure inventarisatie lijkt me prima!!
Waarom zou iemand zich beledigd voelen, als maar duidelijk is dat het om persoonlijke ervaringen gaat en er niet weer mensen gaan prediken dat er een alles helend wondermiddel tussen zit, dat blinde fanatisme vind ik altijd erg storend en jammer
Ook liever geen voorbarige conclusies aan koppelen van 'glutenvrij en vitamine d heeft mijn ms gestopt' of iets van gelijke strekking.
Pure inventarisatie lijkt me prima!!
-
Marsei
Is Chlamydia pneumoniae found in spinal fluid samples from MS patients?
Is Chlamydia pneumoniae found in spinal fluid samples from MS patients?
Is [URL="http://msj.sagepub.com/content/8/4/289.short"][U]Chlamydia pneumoniae[/U][/URL] found in spinal fluid samples from multiple sclerosis patients? Conflicting results
[QUOTE]Cerebrospinal fluid samples from controls and patients with multiple sclerosis (MS) were split and sent to laboratories with different experiences for the detection of Chlamydia pneumoniae by polymerase chain reaction. Vanderbilt investigators identified C. pneumoniae in the majority of patients with MS and uncommonly in controls. Laboratories at Johns Hopkins University, University of Umea3, and the Centers for Disease Control and Prevention did not identify C. pneumoniae in any of the samples. Conflicting reports of C. pneumoniae detection in the same samples from patients with MS highlight the need to exchange detection techniques among laboratories involved in this controversy.[/QUOTE]
Is [URL="http://msj.sagepub.com/content/8/4/289.short"][U]Chlamydia pneumoniae[/U][/URL] found in spinal fluid samples from multiple sclerosis patients? Conflicting results
[QUOTE]Cerebrospinal fluid samples from controls and patients with multiple sclerosis (MS) were split and sent to laboratories with different experiences for the detection of Chlamydia pneumoniae by polymerase chain reaction. Vanderbilt investigators identified C. pneumoniae in the majority of patients with MS and uncommonly in controls. Laboratories at Johns Hopkins University, University of Umea3, and the Centers for Disease Control and Prevention did not identify C. pneumoniae in any of the samples. Conflicting reports of C. pneumoniae detection in the same samples from patients with MS highlight the need to exchange detection techniques among laboratories involved in this controversy.[/QUOTE]
-
Marsei
A combined antibiotic protocol improves the extracranial blood flow
A combined antibiotic protocol improves the extracranial blood flow
A combined antibiotic protocol to treat [URL="https://drive.google.com/file/d/0B1jBdg ... view?pli=1"][U]chronic chlamydophila pneumoniae[/U][/URL] improves the extracranial blood flow in patients with MS and CCSVI - Dr Paul Thibault
Zie [URL="http://www.msweb.nl/forum/showpost.php? ... count=2478"][U]dit bericht [/U][/URL]
A combined antibiotic protocol to treat [URL="https://drive.google.com/file/d/0B1jBdg ... view?pli=1"][U]chronic chlamydophila pneumoniae[/U][/URL] improves the extracranial blood flow in patients with MS and CCSVI - Dr Paul Thibault
Zie [URL="http://www.msweb.nl/forum/showpost.php? ... count=2478"][U]dit bericht [/U][/URL]
-
Marsei
Tried-and-True Antibiotic May Block Conversion to MS
Tried-and-True Antibiotic May Block Conversion to MS
Tried-and-True [URL="http://www.medpagetoday.com/clinical-co ... osis/54038"][U]Antibiotic[/U][/URL] May Block Conversion to MS - Minocycline seemed to reduce progression to multiple sclerosis after first demyelinating event
[QUOTE]In a phase III multicenter Canadian study, patients randomized to minocycline had a significant 44.6% relative risk reduction in progressing to MS over 6 months, reported Luanne Metz, MD, of the University of Calgary, at the European Committee for the Treatment and Research in Multiple Sclerosis meeting.
"We feel that this should be considered a treatment for MS," Metz said. "If you treat people with a simple prescription, you don't need to do complex paperwork or get insurance going. It's a well tolerated drug that requires no safety monitoring whatsoever."[/QUOTE]
Tried-and-True [URL="http://www.medpagetoday.com/clinical-co ... osis/54038"][U]Antibiotic[/U][/URL] May Block Conversion to MS - Minocycline seemed to reduce progression to multiple sclerosis after first demyelinating event
[QUOTE]In a phase III multicenter Canadian study, patients randomized to minocycline had a significant 44.6% relative risk reduction in progressing to MS over 6 months, reported Luanne Metz, MD, of the University of Calgary, at the European Committee for the Treatment and Research in Multiple Sclerosis meeting.
"We feel that this should be considered a treatment for MS," Metz said. "If you treat people with a simple prescription, you don't need to do complex paperwork or get insurance going. It's a well tolerated drug that requires no safety monitoring whatsoever."[/QUOTE]
-
Marsei
ECTRIMS 2015
ECTRIMS 2015
[URL="https://www.youtube.com/watch?v=RIAluxx-YQ4"][U]Video[/U][/URL]: Dr. Daniel Kantor talks about a study on Minocycline reducing the relative risk of Multiple Sclerosis in people experiencing their first clinical demyelinating event.
[URL="https://www.youtube.com/watch?v=RIAluxx-YQ4"][U]Video[/U][/URL]: Dr. Daniel Kantor talks about a study on Minocycline reducing the relative risk of Multiple Sclerosis in people experiencing their first clinical demyelinating event.
-
Marsei
Minocycline reduceert MS bij patiënten met CIS
Minocycline reduceert MS bij patiënten met CIS
[URL="http://medidact.com/neurologie/Congresn ... dded09faf9"][U]Minocycline[/U][/URL] reduceert MS bij patiënten met CIS
[QUOTE]Op zes maanden reduceerde minocycline 100 mg tweemaal daags de absolute risicoreductie van MS met 27,4% en het relatieve risico met 44,6%. Minocycline is een veilige, goed verdraagbare en goedkope orale behandeling die moet worden overwogen bij patiënten met tekenen van demyelinisatie.
Minocycline heeft veel immunomodulerende eigenschappen. Preklinische en preliminaire klinische studies suggereren dat minocycline ziekteactiviteit bij multipele sclerose (MS) moduleert, als monotherapie en als toevoeging aan een andere behandeling.
“In deze fase III-studie wilden we onderzoeken of minocycline 100 mg tweemaal daags het aantal patiënten met klinisch geïsoleerd syndroom (CIS) dat MS ontwikkelt, met minimaal 25% kon reduceren in vergelijking met placebo”, zo legde Metz uit.
“We randomiseerden 142 patiënten tussen de 18 en 60 jaar, met ten minste twee T2-hyperintense laesies op magnetic resonance imaging (MRI) en het eerste teken van klinische demyelinisatie binnen 180 dagen vanaf baseline. Zij werden opgesplitst in hoogrisico- en laagrisicogroepen.”
Patiënten die minocycline kregen, hadden na zes maanden een absolute MS-risicoreductie van 27,4%; de relatieve risicoreductie bedroeg 44,6%.
“Dit is vergelijkbaar met de effectiviteit van andere goedgekeurde behandelingen”, stelde Metz. “Minocycline werkte daarnaast snel.
Uit de subgroepanalyse bleken geen interacties en - conform wat je mag verwachten van een middel dat al tientallen jaren wordt toegepast – er deden zich geen onverwachte veiligheidsissues voor.”[/QUOTE]
[URL="http://medidact.com/neurologie/Congresn ... dded09faf9"][U]Minocycline[/U][/URL] reduceert MS bij patiënten met CIS
[QUOTE]Op zes maanden reduceerde minocycline 100 mg tweemaal daags de absolute risicoreductie van MS met 27,4% en het relatieve risico met 44,6%. Minocycline is een veilige, goed verdraagbare en goedkope orale behandeling die moet worden overwogen bij patiënten met tekenen van demyelinisatie.
Minocycline heeft veel immunomodulerende eigenschappen. Preklinische en preliminaire klinische studies suggereren dat minocycline ziekteactiviteit bij multipele sclerose (MS) moduleert, als monotherapie en als toevoeging aan een andere behandeling.
“In deze fase III-studie wilden we onderzoeken of minocycline 100 mg tweemaal daags het aantal patiënten met klinisch geïsoleerd syndroom (CIS) dat MS ontwikkelt, met minimaal 25% kon reduceren in vergelijking met placebo”, zo legde Metz uit.
“We randomiseerden 142 patiënten tussen de 18 en 60 jaar, met ten minste twee T2-hyperintense laesies op magnetic resonance imaging (MRI) en het eerste teken van klinische demyelinisatie binnen 180 dagen vanaf baseline. Zij werden opgesplitst in hoogrisico- en laagrisicogroepen.”
Patiënten die minocycline kregen, hadden na zes maanden een absolute MS-risicoreductie van 27,4%; de relatieve risicoreductie bedroeg 44,6%.
“Dit is vergelijkbaar met de effectiviteit van andere goedgekeurde behandelingen”, stelde Metz. “Minocycline werkte daarnaast snel.
Uit de subgroepanalyse bleken geen interacties en - conform wat je mag verwachten van een middel dat al tientallen jaren wordt toegepast – er deden zich geen onverwachte veiligheidsissues voor.”[/QUOTE]
-
Marsei
Role of cp in the Pathogenesis of CCSVI in Patients with MS
Role of cp in the Pathogenesis of CCSVI in Patients with MS
Role of [URL="http://www.omicsgroup.org/journals/role ... 4.facebook"][U]Chlamydophila pneumoniae[/U][/URL] in the Pathogenesis of Chronic Cerebrospinal Venous Insuffiency in Patients with Multiple Sclerosis
[QUOTE][B]Conclusion[/B]
CCVSI may be an inflammatory process caused by infection. Among the potential infectious agents that could cause CCVSI, C. pneumoniae seems the most likely candidate. Its association with vascular infections and endothelial dysfunction due to inflammation is well demonstrated, as well as the evidence of a relationship between C. pneumoniae and neurological diseases including MS.
The pathophysiological connection of CCSVI with C. pneumoniae resides on the fact that C. pneumoniae is able to infect large variety of cells including venous endothelial cells in venous tissues thus contributing to an inflammatory-autoimmune process in venous tissue that leads to the venous abnormalities (VM/ occlusions) described in CCSVI.[/QUOTE]
Role of [URL="http://www.omicsgroup.org/journals/role ... 4.facebook"][U]Chlamydophila pneumoniae[/U][/URL] in the Pathogenesis of Chronic Cerebrospinal Venous Insuffiency in Patients with Multiple Sclerosis
[QUOTE][B]Conclusion[/B]
CCVSI may be an inflammatory process caused by infection. Among the potential infectious agents that could cause CCVSI, C. pneumoniae seems the most likely candidate. Its association with vascular infections and endothelial dysfunction due to inflammation is well demonstrated, as well as the evidence of a relationship between C. pneumoniae and neurological diseases including MS.
The pathophysiological connection of CCSVI with C. pneumoniae resides on the fact that C. pneumoniae is able to infect large variety of cells including venous endothelial cells in venous tissues thus contributing to an inflammatory-autoimmune process in venous tissue that leads to the venous abnormalities (VM/ occlusions) described in CCSVI.[/QUOTE]
-
Marsei
Antibiotic protocol improves the extracranial venous circulation in MS
Antibiotic protocol improves the extracranial venous circulation in MS
A prolonged antibiotic protocol to treat persistent [URL="http://journals.sagepub.com/doi/abs/10. ... b%3Dpubmed&"][U]Chlamydophila pneumoniae infection[/U][/URL] improves the extracranial venous circulation in multiple sclerosis - Thibault
[QUOTE][B]Abstract[/B]
[B]Objective[/B]
Chronic cerebrospinal venous insufficiency (CCSVI) is a condition associated with multiple sclerosis (MS). One mechanism that has been proposed is that the venous obstructions found in MS are due to a chronic persistent venulitis caused by the intra-cellular bacterial parasite, Chlamydophila pneumoniae (Cpn). The objective of the current study is to determine the effect of a combined antibiotic protocol (CAP) on the venous flow in MS patients as measured by a quantitative duplex ultrasound examination (QDUS).
[B]Method[/B]
A non-randomised before-after cohort study was conducted to investigate differences in blood flow volumes pre and 6-months post antibiotic treatment for Cpn infection. Flow volume data were measured by QDUS across affected and unaffected sides from multiple veins segments, including internal jugular vein (IJV) segments J2 and J3, and vertebral vein (VV), as well as global arterial blood flow (GABF).
[B]Results[/B]
91 patients were included in the study. 64 (70%) were found to have positive Cpn serology. There was a statistically significant post-treatment difference seen for the affected side of Cpn infected patients (mean difference = 56 mL/min, p = 0.02). There was a non-significant increase seen for the affected side of uninfected patients (mean difference = 23 mL/min, p = 0.2). The difference in these effects (34 mL/min) was not statistically significant (p = 0.3). The mean flow rate decreased in the unaffected side for both infected (−27 mL/min, p = 0.5) and uninfected patients (−69 mL/min, p = 0.01).
There was a statistically significant post-treatment increase in GABF for the infected patients (mean difference = 90 mL/min, p = 0.02) and a difference of 76 mL/min for non-infected patients (p = 0.01).
[B]Conclusion[/B]
A CAP appears to improve the extra-cranial circulation in patients diagnosed with MS. This effect is statistically significant in patients with positive Cpn serology, although patients with negative Cpn serology also show some benefit, betraying a lack of specificity of this effect.[/QUOTE]
A prolonged antibiotic protocol to treat persistent [URL="http://journals.sagepub.com/doi/abs/10. ... b%3Dpubmed&"][U]Chlamydophila pneumoniae infection[/U][/URL] improves the extracranial venous circulation in multiple sclerosis - Thibault
[QUOTE][B]Abstract[/B]
[B]Objective[/B]
Chronic cerebrospinal venous insufficiency (CCSVI) is a condition associated with multiple sclerosis (MS). One mechanism that has been proposed is that the venous obstructions found in MS are due to a chronic persistent venulitis caused by the intra-cellular bacterial parasite, Chlamydophila pneumoniae (Cpn). The objective of the current study is to determine the effect of a combined antibiotic protocol (CAP) on the venous flow in MS patients as measured by a quantitative duplex ultrasound examination (QDUS).
[B]Method[/B]
A non-randomised before-after cohort study was conducted to investigate differences in blood flow volumes pre and 6-months post antibiotic treatment for Cpn infection. Flow volume data were measured by QDUS across affected and unaffected sides from multiple veins segments, including internal jugular vein (IJV) segments J2 and J3, and vertebral vein (VV), as well as global arterial blood flow (GABF).
[B]Results[/B]
91 patients were included in the study. 64 (70%) were found to have positive Cpn serology. There was a statistically significant post-treatment difference seen for the affected side of Cpn infected patients (mean difference = 56 mL/min, p = 0.02). There was a non-significant increase seen for the affected side of uninfected patients (mean difference = 23 mL/min, p = 0.2). The difference in these effects (34 mL/min) was not statistically significant (p = 0.3). The mean flow rate decreased in the unaffected side for both infected (−27 mL/min, p = 0.5) and uninfected patients (−69 mL/min, p = 0.01).
There was a statistically significant post-treatment increase in GABF for the infected patients (mean difference = 90 mL/min, p = 0.02) and a difference of 76 mL/min for non-infected patients (p = 0.01).
[B]Conclusion[/B]
A CAP appears to improve the extra-cranial circulation in patients diagnosed with MS. This effect is statistically significant in patients with positive Cpn serology, although patients with negative Cpn serology also show some benefit, betraying a lack of specificity of this effect.[/QUOTE]
-
Leonard
Minocycline remt de aanmaak van PADs, het enzyme Peptidyl Arginine Deiminase, en daarmee het proces dat tot cel degradatie leidt.
verdere uitleg hier: [url]http://www.thisisms.com/forum/general-d ... ml#p248066[/url]
ik ben er van overtuigd dat dit het verhaal is.
de farma - bedrijven die verantwoording schuldig zijn aan hun aandeelhouders - kan ik niet kwalijk nemen dat ze achter de winst aangaan.
de politiek doet niks en verschuilt zich achter de academische wereld.
de academische wereld en onze eigen MS verenigingen zijn vervuild en denken niet verder dan hun neus lang is.
ik maak me er zo kwaad over..
verdere uitleg hier: [url]http://www.thisisms.com/forum/general-d ... ml#p248066[/url]
ik ben er van overtuigd dat dit het verhaal is.
de farma - bedrijven die verantwoording schuldig zijn aan hun aandeelhouders - kan ik niet kwalijk nemen dat ze achter de winst aangaan.
de politiek doet niks en verschuilt zich achter de academische wereld.
de academische wereld en onze eigen MS verenigingen zijn vervuild en denken niet verder dan hun neus lang is.
ik maak me er zo kwaad over..